Abstract
Objectives: To assess the relationship between disease duration and the prevalence/distribution of nailfold videocapillaroscopy (NVC) patterns, named according to the current classification as “early”, “active”, and “late”, in a large cohort of systemic sclerosis (SSc) patients.
Methods: A cross-sectional analysis was conducted on 1,689 patients undergoing standardised NVC. Clinical-serological data and treatments were collected. Statistical comparisons and multivariable logistic regression models were applied, including analyses based on disease duration.
Results: The prevalence of NVC patterns was as follows: “early” 21.6%, “active” 47.4%, “late” 25.7%, and normal/non-specific 5.3%. The distribution by disease duration showed that the three main patterns were always present. While the “early” and “active” progressively decreased (from 30.3% and 51.9% in patients with ≤5 yrs, to 14.6% and 43.5% in those >10 yrs, p< 0.01), the “late” pattern increased from 13.2% (≤5 yrs) to 36.0% (>10 yrs) (p< 0.001) and was associated with internal organ involvement, anti-topoisomerase antibodies, and more therapies (p< 0.01). Conversely, the “early” and “active” patterns were associated with the limited-cutaneous subset (p< 0.01), and anti-centromere antibodies (p< 0.001). Multivariable analysis confirmed a strong association between the “late” pattern and skin/peripheral vascular involvement. Notably, the presence of the “late” pattern in patients with ≤2 yrs (10.9%) was significantly associated with scleroderma renal crisis (p= 0.012).
Conclusions: SSc-NVC patterns are not strictly time-dependent and can be observed at any stage of the disease, suggesting that microvascular damage progression is heterogeneous across different disease periods. Therefore, a revised classification of NVC changes considering both disease duration and NVC severity could improve its prognostic accuracy.
Keywords: nailfold capillaroscopy patterns; scleroderma; systemic sclerosis.
© The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.